Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 14/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 14/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 14/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 14/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dacinostat SCHEMBL95240 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| Dacinostat SCHEMBL29351399 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949830 | 0.96 | HDAC1 (0.92) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL8237486 | 0.94 | HDAC1 (0.89) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949950 | 0.93 | HDAC1 (0.88) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949996 | 0.93 | HDAC1 (0.88) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL8244899 | 0.93 | HDAC1 (0.87) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949781 | 0.93 | HDAC1 (0.94) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL10324938 | 0.92 | HDAC1 (0.86) | HDAC1HDAC3HDAC8HDAC6HDAC4 | |
| SCHEMBL13949855 | 0.92 | HDAC1 (0.92) | HDAC1HDAC3HDAC8HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 871 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| US-20200368280-A1 | EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY | Viracta Subsidiary, Inc. | 2020-11-26 | — | — | US | claimed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-3407913-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | Indiana University Research & Technology Corporation (US) | 2018-12-05 | — | — | EP | claimed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | claimed |
| EP-1456664-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | Novartis AG (CH) | 2004-09-15 | — | — | EP | claimed |
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | claimed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | claimed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | claimed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | claimed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | claimed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | claimed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC8 10/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | HDAC1 3475/4885HDAC3 2895/4885HDAC8 3881/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.